Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of COPDBethesda (MD)GOLD2016 Available from: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/Accessed October 23, 2015
   Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther201023425726720381630
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEEffects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPDChest2006129350951716537846
   PubMed Web of Science ®Google Scholar
• BertonDCReisMSiqueiraACEffects of tiotropium and for-moterol on dynamic hyperinflation and exercise endurance in COPDRespir Med201010491288129620580216
   PubMed Web of Science ®Google Scholar
• TashkinDPPearleJIezzoniDVargheseSTFormoterol and tiotropium compared with tiotropium alone for treatment of COPDCOPD200961172519229704
   PubMedGoogle Scholar
• VogelmeierCKardosPHarariSGansSJStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med2008102111511152018804362
   PubMed Web of Science ®Google Scholar
• WangJJinDZuoPWangTXuYXiongWComparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysisRespirology201116235035821138499
   PubMed Web of Science ®Google Scholar
• TashkinDPDonohueJFMahlerDAEffects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPDRespir Med2009103451652419208459
   PubMed Web of Science ®Google Scholar
• TashkinDPLittnerMAndrewsCPTomLinsonLRinehartMDenis-MizeKConcomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trialRespir Med2008102447948718258423
   PubMed Web of Science ®Google Scholar
• HananiaNABootaAKerwinETomLinsonLDenis-MizeKEfficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: results from a 6-week, randomized, placebo-controlled, clinical trialDrugs20096991205121619537837
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensECombining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptomsRespir Med20101047995100420303247
   PubMed Web of Science ®Google Scholar
• JonesPWAgustiAGOutcomes and markers in the assessment of chronic obstructive pulmonary diseaseEur Respir J200627482283216585091
   PubMed Web of Science ®Google Scholar
• JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
   PubMed Web of Science ®Google Scholar
• AisanovZBaiCBauerleOPrimary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the worldInt J Chron Obstruct Pulmon Dis2012727128222563246
   PubMed Web of Science ®Google Scholar
• JonesPWDonohueJFNedelmanJPascoeSPinaultGLassenCCorrelating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespir Res20111216122206353
   PubMed Web of Science ®Google Scholar
• JonesPWHealth status measurement in chronic obstructive pulmonary diseaseThorax2001561188088711641515
   PubMed Web of Science ®Google Scholar
• WestwoodMBourbeauJJonesPWCerulliACapkun-NiggliGWorthyGRelationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic reviewRespir Res2011124021477298
   PubMed Web of Science ®Google Scholar
• HarunaAOgaTMuroSRelationship between peripheral airway function and patient-reported outcomes in COPD: a cross-sectional studyBMC Pulm Med2010101020205936
   PubMed Web of Science ®Google Scholar
• WatsonLSchoutenJPLöfdahlCGPrideNBLaitinenLAPostmaDSPredictors of COPD symptoms: does the sex of the patient matter?Eur Respir J200628231131816707516
   PubMed Web of Science ®Google Scholar
• DonohueJFJonesPBartelsCRelationship between change in trough FEV1 and COPD patient outcomes: pooled analysis of 23 clinical trials in patients with COPDEur Respir J201546Suppl 59PA1013
   Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med200967e100009719621072
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• ZhongNWangCZhouXLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
   PubMed Web of Science ®Google Scholar
• BuhlRGessnerCSchuermannWEfficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to severe COPD (QUANTIFY): a randomised, non-inferiority studyThorax201570431131925677679
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• DonohueJFWorsleySZhuCQHardakerLChurchAImprovements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med2015109787088126006754
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMMergelVLeslbaumARCaractaCFEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• BeehKMWestermanJKirstenAMThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
   PubMed Web of Science ®Google Scholar
• MaltaisFSinghSDonaldACEffects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trialsTher Adv Respir Dis20148616918125452426
   PubMed Web of Science ®Google Scholar
• O’DonnellDCasaburiRDe SousaDEffects of 6 weeks’ treatment with once-daily tiotropium and olodaterol fixed-dose combination on inspiratory capacity and exercise endurance in patients with COPD: the MORACTO studiesAm J Respir Crit Care Med20151911A3972
   Google Scholar
• BeehKMKornSBeierJEffect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT studyRespir Med2014108458459224534204
   PubMed Web of Science ®Google Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med2013107101558156723867808
   PubMed Web of Science ®Google Scholar
• DahlRJadayelDAlagappanVKChenHBanerjiDEfficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyInt J Chron Obstruct Pulmon Dis2013850150824159259
   PubMed Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE studyEur Respir J20144361599160924176997
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• DonohueJFSinghDMunzuCKilbrideSChurchAMagnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trialsRespir Med2016112657426797016
   PubMed Web of Science ®Google Scholar
• SinghDWorsleySZhuCQHardakerLChurchAUmeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trialBMC Pulm Med2015159126286141
   PubMed Web of Science ®Google Scholar
• DonohueJFNiewoehnerDBrooksJO’DellDChurchASafety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyRespir Res2014157825015176
   PubMed Web of Science ®Google Scholar
• MaltaisFIturraJBKirstenAEffects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPDEur Respir J201444Suppl 58P283
   Google Scholar
• DonohueJFSoongWWuXShresthaPLeiALong-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPDRespir Med2016116414827296819
   PubMed Web of Science ®Google Scholar
• VogelmeierCPaggiaroPLDorcaJEfficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD studyEur Respir J20164841030103927492833
   PubMed Web of Science ®Google Scholar
• ReisnerCRoseEStromSFixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2B study in patients with COPDEur Respir J201138Suppl 55P879
   Google Scholar
• ReisnerCRennardSFogartyCPearl Therapeutics’ combination LAMA/LABA MDI (GFF-MDI, PT003) provides a significant benefit on home peak expiratory flow rate (PEFR) and reduces the need for rescue albuterol use compared to its components administered alone, Spiriva Handihaler, and Foradil Aerolizer in a randomized, double-blind, placebo-controlled phase 2B study in patients with COPDPoster presented at: American Thoracic Society (ATS) International ConferenceMay 18–23, 2012San Francisco, CA
   Google Scholar
• ReisnerCGotfriedMDenenbergMBLow doses of Pearl Therapeutics’ LAMA/LABA combination MDI (GFF MDI, PT003) provide superior bronchodilation compared to components and to open-label Spiriva HandiHaler in a randomized, double-blind, placebo-controlled Phase IIB study in patients with COPDPoster presented at: American Thoracic Society (ATS) International ConferenceMay 17–22, 2013Philadelphia, PA
   Google Scholar
• ChapmanKRBatemanEDOlssonPChenHBanerjiDFogelRA significant proportion of patients with COPD show marked improvements in lung function with QVA149 (high responders): a post-hoc analysis of the SHINE studyChronic Obstr Pulm Dis201522159
   Google Scholar
• BatemanEDVogelmeierCChenHBanerjiDComparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE studyChest20141453409A
   Web of Science ®Google Scholar
• JonesPWSt. George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• WedzichaJADahlRBuhlRPooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patientsRespir Med2014108101498150725135743
   PubMed Web of Science ®Google Scholar
• FergusonGBarnesNMehtaRD’AndreaPChenHBanerjiDCardio- and cerebro-vascular safety profile of QVA149 in patients with COPD: a pooled analysisAm J Respir Crit Care Med20131871A1488
   Google Scholar
• Van de MaeleBFabbriLMMartinCHortonRDolkerMOverendTCardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patientsCOPD20107641842721166630
   PubMedGoogle Scholar
• US Food Drug AdministrationNDA 203-975 umeclidinium and vilanterol inhalation powder for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)2013 Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pulmonary-allergydrugsadvisorycommittee/ucm367411.pdfAccessed October 23, 2015
   Google Scholar
• NaccarelliGFinkleJChopraBBrooksJHarrisSChurchACardiovascular safety of umeclidinium/vilanterol in COPD: results from eight randomized clinical trialsPoster presented at: American Thoracic Society (ATS) International ConferenceMay 16–21, 2014San Diego, CA
   Google Scholar
• ManoharanAShortPMAndersonWJLipworthBJImpact of long-acting bronchodilator therapy on mortality in COPD: a real-life retrospective cohort studyThorax201368Suppl 3A179A180
   Web of Science ®Google Scholar
• Di MarcoFMilic-EmiliJBoveriBEffect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPDEur Respir J2003211869412570114
   PubMed Web of Science ®Google Scholar
• RocheNReddelHKAgustiAIntegrating real-life studies in the global therapeutic research frameworkLancet Respir Med2013110e29e3024461762
   PubMed Web of Science ®Google Scholar
• AsaiKMinakataYHirataKQVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE studyEur Respir J201342Suppl 57694s
   Google Scholar
• D’UrzoARennardSKerwinEOne-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: the AUGMENT COPD studyPoster presented at: European Respiratory Society (ERS) International CongressSeptember 6–10, 2014Munich
   Google Scholar